GP (33-41) (TFA)

• Description:

  GP (33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP (33-41) TFA can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM[1].

• UNSPSC:

  12352209

• Target:

  Arenavirus

• Type:

  Peptides

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/gp-33-41-tfa.html

• Purity:

  99.62

• Solubility:

  DMSO : ≥ 50 mg/mL|H2O : 1.82 mg/mL (ultrasonic; adjust pH to 4 with HCl)

• Smiles:

  O=C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CS)C(O)=O)=O)=O)=O)CC1=CC=CC=C1)=O)[C@@H](NC([C@H](C(C)C)NC([C@H](C)NC([C@@H](N)CCCCN)=O)=O)=O)CC(C=C2)=CC=C2O.OC(C(F)(F)F)=O

• Molecular Formula:

  C48H70F3N11O15S

• Molecular Weight:

  1130.19

• References & Citations:

  [1]Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69 (4) :2297-305.|[2]Boulter JM, et al. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol. 2007 Mar;37 (3) :798-806.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported